During 2018 Q4 the big money sentiment decreased to 1.06. That’s change of 0.23, from 2018Q3’s 1.29. 8 investors sold all, 10 reduced holdings as Galectin Therapeutics, Inc. ratio fall. 9 increased holdings while 10 funds took holdings. Funds hold 4.77 million shares thus 7.28% less from 2018Q3’s 5.15 million shares.
Bluecrest Capital Management has invested 0.01% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Goldman Sachs Gru owns 14,068 shs for 0% of their capital. Pnc Fincl Grp holds 47,164 shs or 0% of its capital. Stratos Wealth Prns invested 0.01% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Fmr Ltd Llc holds 0% or 800 shs in its capital. Geode Mngmt owns 227,175 shs. Blackrock Inc owns 604,268 shs or 0% of their US capital. State Street stated it has 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Boothbay Fund Lc stated it has 30,562 shs. Moreover, Buckingham Asset has 0.01% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 10,000 shs. Susquehanna International Group Incorporated Ltd Liability Partnership owns 163,109 shs. Cutter And Company Brokerage invested in 0.08% or 57,800 shs. Optimum Advisors has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Cetera Advisor Networks Ltd Co stated it has 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Bancshares Of America Corp De invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT).

Galectin Therapeutics, Inc. had 1 insider sale and 5 insider buys since September 25, 2018. This’s net activity of $128,476. On Friday, February 8 $6,428 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was bought by FREEMAN KEVIN D. 1,000 Galectin Therapeutics, Inc. (NASDAQ:GALT) shs with value of $4,805 were bought by LEWIS JOEL. 30,000 shs were sold by AMELIO GILBERT F, worth $150,000 on Wednesday, January 30. 2,000 shs valued at $12,200 were bought by ELDRED KARY on Tuesday, September 25.

On April, 4 is expected Galectin Therapeutics, Inc. (NASDAQ:GALT)’s earnings report, Zacks reports. Analysts have anticipation on stock’s earnings per share of $-0.08. That’s down 14.29 % from last year?s $-0.07 earnings per share. 14.29 % negative EPS growth is what Wall Street’s forecasts after $-0.07 reported EPS last quarter. $4.73 was the last price.Since March 11, 2018 it’s 31.58% down thus uptrending. GALT outperformed by 27.21% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

In total 2 analysts cover Galectin Therapeutics (NASDAQ:GALT). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:GALT) has 100% bullish analysts. 4 are the (NASDAQ:GALT)’s ratings reports on Mar 11, 2019 according to StockzIntelligence Inc. The stock rating was initiated by FBR Capital with “Buy” on Thursday, March 7. On Thursday, March 7 the firm earned “Buy” rating by H.C. Wainwright.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer.The firm is worth $194.83 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.Currently it has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

For more Galectin Therapeutics, Inc. (NASDAQ:GALT) news brought out briefly go to: Seekingalpha.com, Seekingalpha.com, Benzinga.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Galectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300% – Seeking Alpha” brought out on January 29, 2018, “Piper likes OncoCyte in premarket analyst action – Seeking Alpha” on February 13, 2019, “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares – Benzinga” with a publish date: June 19, 2018, “Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit – GlobeNewswire” and the last “Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting – GlobeNewswire” with publication date: November 05, 2018.